Indication: Quetiapine tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia (1. 1) Bipolar I disorder manic episodes (1. 2) Bipolar disorder, depressive episodes (1. 2) Quetiapine tablets are indicated for the treatment of schizophrenia. The efficacy of quetiapine tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14. 1) Quetiapine tablets are indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see Clinical Studies (14. 2) [see Clinical Studies (14. 2) Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Indication: Quetiapine tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia (1. 1) Bipolar I disorder manic episodes (1. 2) Bipolar disorder, depressive episodes (1. 2) Quetiapine tablets are indicated for the treatment of schizophrenia. The efficacy of quetiapine tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14. 1) Quetiapine tablets are indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see Clinical Studies (14. 2) [see Clinical Studies (14. 2) Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Indication: Olanzapine tablets are an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. 1 Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. 1 Adolescents (ages 13 to 17): Efficacy was established in one 6-­ week trial in patients with schizophrenia ( 14. 1 Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. 2 Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. 2 Adolescents (ages 13 to 17): Efficacy was established in one 3­- week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14. 2 Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. 3 Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. 2 Efficacy was established in two 6-week clinical trials in adults ( 14. 2 As Olanzapine tablets and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. 5 Efficacy was established with Symbyax (olanzapine and fluoxetine in combination); refer to the product label for Symbyax. Treatment of treatment resistant depression. 6 Efficacy was established with Symbyax (olanzapine and fluoxetine in combination) in adults; refer to the product label for Symbyax. Oral olanzapine tablets are indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see Clinical Studies ( 14. 1 When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions ( 5. 5 Monotherapy [see Clinical Studies ( 14. 2 When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. 5 Adjunctive Therapy to Lithium or Valproate [see Clinical Studies ( 14. 2 Pediatric schizophrenia and bipolar I disorder are serious mental disorders; however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, pediatric patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder should be part of a total treatment program that often includes psychological, educational and social interventions. Oral olanzapine tablets and fluoxetine in combination is indicated for the treatment of depressive episodes associated with bipolar I disorder, based on clinical studies. When using olanzapine tablets and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine tablets monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder. Oral olanzapine and fluoxetine in combination is indicated for the treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode), based on clinical studies in adult patients. When using olanzapine and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine monotherapy is not indicated for the treatment of treatment resistant depression.

Indication: Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: · Treatment of schizophrenia. 1 · Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. 1 · Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14. 1 · Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. 2 · Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. 2 · Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14. 2 · Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. 3 · Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. 2 · Efficacy was established in two 6-week clinical trials in adults ( 14. 2 As Olanzapine and Fluoxetine in Combination for the: 1. 6 Oral olanzapine tablets are indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see Clinical Studies ( 14. 1 When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions ( 5. 5 Monotherapy [see Clinical Studies ( 14. 2 When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. 5 Adjunctive Therapy to Lithium or Valproate [see Clinical Studies ( 14. 2 Pediatric schizophrenia and bipolar I disorder are serious mental disorders; however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, pediatric patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder should be part of a total treatment program that often includes psychological, educational and social interventions. Oral olanzapine and fluoxetine in combination is indicated for the treatment of depressive episodes associated with bipolar I disorder, based on clinical studies. When using olanzapine and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder. Oral olanzapine and fluoxetine in combination is indicated for the treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode), based on clinical studies in adult patients.

Indication: Quetiapine tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia (1. 1) Bipolar I disorder manic episodes (1. 2) Bipolar disorder, depressive episodes (1. 2) Quetiapine tablets are indicated for the treatment of schizophrenia. The efficacy of quetiapine tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14. 1) Quetiapine tablets are indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see Clinical Studies (14. 2) [see Clinical Studies (14. 2) Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Indication: Lurasidone hydrochloride is indicated for: Treatment of adult patients and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14. 1 Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14. 2 Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14. 2 Lurasidone hydrochloride tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults and adolescents (13 to 17 years) ( 1 14. 1 Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy ( 1 14. 2 Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate ( 1 14.

Indication: Aripiprazole tablets are indicated for the treatment of: Schizophrenia Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. The oral formulation is indicated for: Schizophrenia (14. 1) Irritability Associated with Autistic Disorder ( 14. 4 Treatment of Tourette’s disorder ( 14.

Indication: Quetiapine tablets, USP are an atypical antipsychotic indicated for the treatment of Schizophrenia ( 1. 1 Bipolar I disorder manic episodes ( 1. 2 Bipolar disorder, depressive episodes ( 1. 2 Quetiapine tablets, USP are indicated for the treatment of schizophrenia. The efficacy of Quetiapine tablets, USP in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13-17 years). The effectiveness of Quetiapine tablets, USP for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [ see Clinical Studies ( 14. 1 Quetiapine tablets, USP are indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10-17 years) [ see Clinical Studies ( 14. 2 Quetiapine tablets, USP are indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies ( 14. 2 Quetiapine tablets, USP are indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine tablets, USP as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials [ see Clinical Studies ( 14. 2 Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Indication: INDICATIONS AND USAGE
Ziprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone''s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions ( 5. 3 [see Warnings and Precautions ( 5. 3 Schizophrenia Ziprasidone is indicated for the treatment of schizophrenia in adults [see Clinical Studies ( 14. 1 Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate) Ziprasidone is indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies ( 14. 2 Ziprasidone is indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder in adults [see Clinical Studies ( 14. 2 Ziprasidone is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of ziprasidone to prolong the QT interval and may consider the use of other drugs first ( 1 Ziprasidone capsules are indicated for the: treatment of schizophrenia in adults. ( 1 acute treatment of adults as monotherapy of manic or mixed episodes associated with bipolar I disorder. ( 1 maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults.
SPL PATIENT PACKAGE INSERT
PATIENT SUMMARY OF INFORMATION ABOUT Ziprasidone ( zi pras'' i done ) Capsules, USP Information for patients taking ziprasidone capsules or their caregivers This summary contains important information about ziprasidone capsules. It is not meant to take the place of your doctor''s instructions. Read this information carefully before you take ziprasidone capsules. Ask your doctor or pharmacist if you do not understand any of this information or if you want to know more about ziprasidone capsules. What Are Ziprasidone Capsules? Ziprasidone capsules are a type of prescription medicine called a psychotropic, also known as an atypical antipsychotic. Ziprasidone capsules can be used to treat symptoms of schizophrenia and acute manic or mixed episodes associated with bipolar disorder. Ziprasidone capsules can also be used as maintenance treatment of bipolar disorder when added to lithium or valproate. Who Should Take Ziprasidone Capsules? Only your doctor can know if ziprasidone capsules are right for you. Ziprasidone capsules may be prescribed for you if you are an adult with schizophrenia or bipolar disorder. Symptoms of schizophrenia may include: hearing voices, seeing things, or sensing things that are not there (hallucinations) beliefs that are not true (delusions) unusual suspiciousness (paranoia) becoming withdrawn from family and friends Symptoms of manic or mixed episodes of bipolar disorder may include: extremely high or irritable mood increased energy, activity, and restlessness racing thoughts or talking very fast easily distracted little need for sleep If you show a response to ziprasidone capsules, your symptoms may improve. If you continue to take ziprasidone capsules there is less chance of your symptoms returning. Do not stop taking the capsules even when you feel better without first discussing it with your doctor. It is also important to remember that ziprasidone capsules should be taken with food. What is the most important safety information I should know about ziprasidone capsules? Ziprasidone capsules are not approved for the treatment of patients with dementia-related psychosis. Elderly patients with a diagnosis of psychosis related to dementia treated with antipsychotics are at an increased risk of death when compared to patients who are treated with placebo (a sugar pill). Ziprasidone capsules are an effective drug to treat the symptoms of schizophrenia and the manic or mixed episodes of bipolar disorder. However, one potential side effect is that it may change the way the electrical current in your heart works more than some other drugs. The change is small and it is not known whether this will be harmful, but some other drugs that cause this kind of change have in rare cases caused dangerous heart rhythm abnormalities . Your risk of dangerous changes in heart rhythm can be increased if you are taking certain other medicines and if you already have certain abnormal heart conditions. Therefore, it is important to tell your doctor about any other medicines that you take, including non-prescription medicines, supplements, and herbal medicines. You must also tell your doctor about any heart problems you have or have had. Who should NOT take ziprasidone capsules? Elderly patients with a diagnosis of psychosis related to dementia. Ziprasidone capsules are not approved for the treatment of these patients. Anything that can increase the chance of a heart rhythm abnormality should be avoided. Therefore, do not take ziprasidone capsules if: You have certain heart diseases, for example, long QT syndrome, a recent heart attack, severe heart failure, or certain irregularities of heart rhythm (discuss the specifics with your doctor) You are currently taking medications that should not be taken in combination with ziprasidone, for example, dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. What To Tell Your Doctor Before You Start Ziprasidone Capsules Only your doctor can decide if ziprasidone capsules are right for you. Before you start ziprasidone capsules, be sure to tell your doctor if you: have had any problem with the way your heart beats or any heart related illness or disease any family history of heart disease, including recent heart attack have had any problem with fainting or dizziness are taking or have recently taken any prescription medicines are taking any over-the-counter medicines you can buy without a prescription, including natural/herbal remedies have had any problems with your liver are pregnant, might be pregnant, or plan to get pregnant are breast feeding or plan to breast feed are allergic to any medicines have ever had an allergic reaction to ziprasidone or any of the other ingredients of ziprasidone capsules. Ask your doctor or pharmacist for a list of these ingredients have low levels of potassium or magnesium in your blood Your doctor may want you to get additional laboratory tests to see if ziprasidone capsules are an appropriate treatment for you. Ziprasidone Capsules And Other Medicines There are some medications that may be unsafe to use when taking ziprasidone capsules, and there are some medicines that can affect how well ziprasidone capsule works. While you are on ziprasidone capsules, check with your doctor before starting any new prescription or over-the-counter medications, including natural/herbal remedies. How To Take Ziprasidone Capsules Take ziprasidone capsules only as directed by your doctor. Swallow ziprasidone capsules whole. Do not chew, crush, or open the capsules. Take ziprasidone capsules with food. It is best to take ziprasidone capsules at the same time each day. Ziprasidone capsules may take a few weeks to work. It is important to be patient. Do not change your dose or stop taking your medicine without your doctor''s approval. Remember to keep taking your capsules, even when you feel better. Possible Side Effects Because these problems could mean you''re having a heart rhythm abnormality, contact your doctor IMMEDIATELY Faint or lose consciousness Feel a change in the way that your heart beats (palpitations) Common side effects of ziprasidone capsules include the following and should also be discussed with your doctor if they occur: Adults: Feeling unusually tired or sleepy Nausea or upset stomach Constipation Dizziness Restlessness Abnormal muscle movements, including tremor, shuffling, and uncontrolled involuntary movements Diarrhea Rash Increased cough / runny nose If you develop any side effects that concern you, talk with your doctor. It is particularly important to tell your doctor if you have diarrhea, vomiting, or another illness that can cause you to lose fluids. Your doctor may want to check your blood to make sure that you have the right amount of important salts after such illnesses. For a list of all side effects that have been reported, ask your doctor or pharmacist for the ziprasidone capsules Professional Package Insert. What To Do For An Overdose In case of an overdose, call your doctor or poison control center right away or go to the nearest emergency room. Other Important Safety Information A serious condition called neuroleptic malignant syndrome (NMS) can occur with all antipsychotic medications including ziprasidone capsules. Signs of NMS include very high fever, rigid muscles, shaking, confusion, sweating, or increased heart rate and blood pressure. NMS is a rare but serious side effect that could be fatal. Therefore, tell your doctor if you experience any of these signs. Delayed-onset drug reaction called drug reaction with eosinophilia and systemic symptoms (DRESS) can occur with ziprasidone. Signs of DRESS may include rash, fever, and swollen lymph nodes. Other severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome can occur with ziprasidone. Signs of Stevens-Johnson syndrome may include rash with blisters which could include ulcers in mouth, skin shedding, fever and target-like spots in the skin. DRESS and other SCAR are sometimes fatal; therefore, tell your doctor immediately if you experience any of these signs. Adverse reactions related to high blood sugar (hyperglycemia), sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with ziprasidone capsules, and it is not known if ziprasidone is associated with these reactions. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia. Dizziness caused by a drop in your blood pressure may occur with ziprasidone capsules, especially when you first start taking this medication or when the dose is increased. If this happens, be careful not to stand up too quickly, and talk to your doctor about the problem. Before taking ziprasidone capsules, tell your doctor if you are pregnant or plan on becoming pregnant. If you become pregnant while receiving ziprasidone capsules, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ are breastfeeding or plan to breastfeed. Ziprasidone can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive ziprasidone capsules. Because ziprasidone capsules can cause sleepiness, be careful when operating machinery or driving a motor vehicle. Since medications of the same drug class as ziprasidone capsules may interfere with the ability of the body to adjust to heat, it is best to avoid situations involving high temperature or humidity. It is best to avoid consuming alcoholic beverages while taking ziprasidone capsules. Call your doctor immediately Ziprasidone capsules have not been shown to be safe or effective in the treatment of children and teenagers under the age of 18 years old. Keep ziprasidone capsules and all medicines out of the reach of children. How To Store Ziprasidone Capsules? Store ziprasidone capsules between 68°F to 77°F (20°C to 25°C). For More Information About Ziprasidone Capsules This sheet is only a summary. Ziprasidone capsules are a prescription medicine and only your doctor can decide if it is right for you. If you have any questions or want more information about ziprasidone, talk with your doctor or pharmacist. Brands listed are trademarks of their respective owners. Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.

Indication: Cariprazine capsules are indicated for the: Treatment of schizophrenia in adults [see Clinical Studies ( 14. 1 Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14. 2 Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14. 3 Cariprazine is an atypical antipsychotic indicated for the: Treatment of schizophrenia in adults ( 1 Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults ( 1 Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults ( 1.